Table 1.

Population-Weighted Efficacy of Palivizumab in Children at High Risk for Severe RSV Disease

Underlying Condition	Estimated Population Size	Estimated Annual Population Receiving Palivizumab (% of Population)	Condition-Specific Relative Risk Reduction in RSV-Related Hospitalization, % (P Value)
Children ≤24 mo with BPD	43,000*	10,900 (25)	39 (0.038)
Children ≤24 mo with moderate/severe CHD	19,300†	6600 (34)	45 (0.003)
Preterm infants <32 wk GA and age ≤6 mo without BPD or CHD	,44,800‡	36,500 (81)	72 (0.027)
Preterm infants 32–35 wk GA and age ≤6 mo without BPD or CHD	159,000‡	23,600 (15)	82§ (0.001)

AAP, American Academy of Pediatrics; BPD, bronchopulmonary dysplasia; CHD, congenital heart disease; wk GA, weeks' gestational age; RSV, respiratory syncytial virus; *Data source^10,12; ^†Data source¹¹; ^‡Data source⁹; ^§Among preterm infants 32–35 wk GA with 2012 AAP risk factors (attends child care or has ≥1 older child <5 y of age living in the same household; excluding multiple-birth siblings <1 y of age), efficacy was consistent at 93% (RSV-related hospitalization: 12.5% for placebo vs 0.9% for palivizumab; P = 0.004).